|Target||respiratory syncytial virus fusion protein|
|Chemical and physical data|
|Molar mass||146054.41 g·mol−1|
Suptavumab (INN; development code (REGN2222) is a humanized monoclonal antibody designed for the prevention of medically attended lower respiratory tract disease due to respiratory syncytial virus.
- World Health Organization (2016). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 115" (PDF). WHO Drug Information. 30 (2).
- Statement On A Nonproprietary Name Adopted By The USAN Council - Suptavumab, American Medical Association.
- "Regeneron to Discontinue Development of Suptavumab for Respiratory Syncytial Virus" (Press release). Regeneron. August 14, 2017.